Companies & Markets: Abbott Laboratories Dominates the Global Bare Metal Stents Market

LONDON--(BUSINESS WIRE)-- The global Bare Metal Stents (BMS) market was estimated to be worth about $1billion in 2010. The BMS market has declined from $1.9 billion in 2003 at a Compound Annual Growth Rate (CAGR) of 8.5%. The popularity and affordability of Drug Eluting Stents (DES) is negatively affecting the BMS market. The BMS market is expected to decline at a CAGR of 1.8% until 2017. However, the volumes of BMS are expected to rise due to a decrease in the prices of BMS, thereby leading to an increase in their affordability. An increase in the incidence of CHD will lead to an increase in the use of coronary stents in its treatment. In the US, at the current growth rate, the prevalence of the disease will rise to 9.3% by 2030 from 8% in 2010. This will lead to an increase of about eight million patients suffering from CHD.

The bare metal stents market in the US was estimated at $417m in 2010, declining at a CAGR of 11.6% during the period 2003-2010. The revenues were negatively affected by the introduction of DES in 2003 and their acceptance in the treatment of CHD. The BMS market revived during the period 2005-2008, from $210.9m in 2005 to $513.8m in 2008. The market increased due to cautionary warnings on the use of DES, leading to an increased use of BMS.The US is followed by Japan in being the second largest BMS market, valued at $200m in 2010.

Abbott Laboratories leads the global BMS market, with a share of 58%. Medtronic Inc. is the next largest player after Abbott Laboratories, with a market share of 16%. The entry of new players, such as Biosensors International and MicroPort Scientific Corporation, is leading to increased competition in the bare metal stents market.

This report provides data, information and analysis on the global bare metal stents market. The report provides market landscape, competitive landscape and market trends information on the bare metal stents market. The report provides information on the key trends affecting the market, and key analytical content on the market dynamics.

Bare Metal Stents (BMS) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

http://www.companiesandmarkets.com/r.ashx?id=7BPYOB3W3701720?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Paul Chapman
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Cardiology  Clinical Trials

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.